Claims
- 1. A method for treating cancer, comprising administering to a patient an effective amount of a protein having a receptor-antagonizing domain and an angiogensis inhibiting domain.
- 2. A method according to claim 1, wherein the receptor-antagonizing domain is a prolactin-antagonist domain.
- 3. A method according to claim 1, wherein the angiogensis inhibiting domain is endostatin.
- 4. A method according to claim 1, wherein the protein is a prolactin antagonist-endostatin fusion protein.
- 5. A method according to claim 1, wherein the angiogensis inhibiting domain is angiostatin.
- 6. A method according to claim 1, wherein the protein is a prolactin antagonist-angistatin fusion protein.
- 7. A method according to claim 1, wherein the angiogensis inhibiting domain is Flk-1-bp.
- 8. A method according to claim 1, wherein the protein is a prolactin antagonist-Flk-1-bp fusion protein.
- 9. A method according to claim 2, wherein the prolactin-antagonist domain is characterized by a single amino acid substitution from Glycine to Arginine at position corresponding to 129 of the prolactin protein.
- 10. A method according to claim 2, wherein the prolactin-antagonist domain comprises a protein having the amino acid sequence of SEQ ID NO.: 1 (HPRLA) or a conservative variant thereof.
- 11. A method according to claim 2, wherein the prolactin-antagonist domain comprises a truncation of a native prolactin sequence or a conservative variant thereof.
- 12. A method according to claim 3, wherein the cancer is characterized as expressing a prolactin receptor.
- 13. A method according to claim 1, wherein the receptor-antagonizing domain is an apoptosis-promoting domain.
- 14. A method according to claim 13, wherein the apoptosis-promoting domain functions by inhibiting STAT-5 phosphorylation in a targeted cell.
- 15. A protein, comprising a receptor antagonizing domain and an angiogenesis inhibiting domain.
- 16. A protein according to claim 15, wherein the receptor antagonizing domain is an apoptosis-promoting domain.
- 17. A protein according to claim 15, wherein the apoptosis-promoting domain is a prolactin-antagonist domain.
- 18. A protein according to claim 16, wherein the angiogenesis inhibiting domain is endostatin.
- 19. A protein according to claim 16, wherein the angiogenesis inhibiting domain is angiostatin.
- 20. A protein according to claim 16, wherein the angiogenesis inhibiting domain is FLK-1-bp.
- 21. A protein according to claim 16, wherein the prolactin-antagonist domain is characterized by a single amino acid substitution from Glycine to Arginine at position corresponding to 129 of the prolactin domain.
- 22. A protein according to claim 21, wherein the prolactin-antagonist domain comprises a protein having the amino acid sequence of SEQ ID NO.: 1 (hPRLA), or a conservative variant thereof.
- 23. A protein according to claim 22, wherein the prolactin-antagonist domain comprises a truncation of a native prolactin sequence or a conservative variant thereof.
- 24. A protein according to claim 22, wherein the apoptosis-promoting domain functions by inhibiting STAT-5 phosphorylation in a targeted cell.
- 25. A protein comprising a first domain having the amino acid sequence of SEQ ID NO.: 1, or a conservative variant sequence thereof, and a positive immunomodulator domain.
- 26. A pharmaceutical composition comprising a therapeutically useful amount of the protein of claim 15 and a suitable amount of carrier vehicle.
STATEMENT REGARDING PRIORITY
[0001] This application claims priority to U.S. Provisional Application No. 60/384,121, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The present invention was supported in part by the Endowment Fund of the Greenville Hospital System and Grants (DAMD17-99-1-9129, DAMD17-01-1-0207, NIH/NCI 1R21CA87093).
Provisional Applications (1)
|
Number |
Date |
Country |
|
60384121 |
May 2002 |
US |